Please login to the form below

Not currently logged in
Email:
Password:

FDA gives green light for Erbitux in new cancer indication

BMS and Lilly win approval to market the drug for late-stage head and neck cancer

Bristol-Myers Squibb (BMS) and Eli Lilly have won approval in the US to market Erbitux as a treatment for late-stage head and neck cancer, adding to its existing indications in earlier stages of the disease and colon cancer.

First launched in 2006, Erbitux (cetuximab) remains a growth product for both BMS and Lilly as they prepare for life after patent expiries for some of their top-selling products, and the new approval will lend some welcome additional momentum to their oncology franchises.

According to the US National Cancer Institute, head and neck cancers account for 3-5 per cent of all cancers in the US.

The Food and Drug Administration (FDA) has approved Erbitux for use alongside chemotherapy in patients with advanced, metastatic head and neck cancer on the back of a 442-patient trial which showed that the regimen could extend survival compared to one based on chemotherapy alone.

"Erbitux's ability to extend the lives of patients with head and neck cancers is an important tool for oncologists who often rely on a multi-treatment approach for patients," said the FDA's Richard Pazdur, who heads the haematology and oncology products division of the Center for Drug Evaluation and Research.

"Given the aggressive nature of head and neck cancers that cannot be treated with surgery and radiation, it is important that patients have as many treatment options available as possible," he added.

BMS booked $510m in Erbitux sales in the first nine months of the year, a rise of 3 per cent over the same period of 2010, almost all of which came from the US as rights elsewhere are held by Germany's Merck KGaA.

Meanwhile Lilly, whose ImClone unit originally developed the drug, recognises net royalties on Erbitux sales and revenue from manufactured product sold to its marketing partners. The company made $300m from the product in the first nine months of the year.

Lilly and BMS are also in the latter stages of developing Erbitux as a first- and second-line treatment for non-small cell lung cancer and as a first-line therapy for colorectal cancer.

8th November 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics